Cargando…

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma

Uveal melanoma is the most common primary intraocular malignancy in adults, with a very high mortality rate due to frequent liver metastases. Consequently, the therapy of uveal melanoma remains a major clinical challenge and new treatment approaches are needed. For improving diagnosis and designing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Treszl, Andrea, Steiber, Zita, Schally, Andrew V., Block, Norman L, Dezso, Balazs, Olah, Gabor, Rozsa, Bernadett, Fodor, Klara, Buglyo, Armin, Gardi, Janos, Berta, Andras, Halmos, Gabor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858558/ https://www.ncbi.nlm.nih.gov/pubmed/24077773

Ejemplares similares

Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer
por: Szabó, Zsuzsanna, et al.
Publicado: (2021)

The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma
por: Fodor, Klara, et al.
Publicado: (2020)

Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines
por: Sipos, Eva, et al.
Publicado: (2018)

Concurrence of chromosome 3 and 4 aberrations in human uveal melanoma
por: Sipos, Eva, et al.
Publicado: (2017)

Correlation between the Expression of Angiogenic Factors and Stem Cell Markers in Human Uveal Melanoma
por: Fodor, Klára, et al.
Publicado: (2020)

Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma
por: Harda, Kristof, et al.
Publicado: (2018)

Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels
por: Popovics, Petra, et al.
Publicado: (2014)

Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes
por: He, Yingna, et al.
Publicado: (2010)

Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing Hormone-Releasing Hormone ((99m)Tc/Re-Acdien-LHRH) Conjugates for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH Receptor
por: Calderon, Lindsay E., et al.
Publicado: (2021)

Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment
por: Ichaoui, Hamza, et al.
Publicado: (2019)

Enhanced Anti-Tumoral Activity of Methotrexate-Human Serum Albumin Conjugated Nanoparticles by Targeting with Luteinizing Hormone-Releasing Hormone (LHRH) Peptide
por: Taheri, Azade, et al.
Publicado: (2011)

LHRH analogues and breast cancer.
por: Korkut, E., et al.
Publicado: (1991)

Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: Novel Therapeutic Approaches
por: Szabo, Zsuzsanna, et al.
Publicado: (2022)

Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial
por: Tree, Alison, et al.
Publicado: (2022)

Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone
por: Jaszberenyi, Miklos, et al.
Publicado: (2013)

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture
por: Wilson, Hannah C.P., et al.
Publicado: (2015)

Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome
por: Liu, Nana, et al.
Publicado: (2012)

Characterization of Luteinizing Hormone and Luteinizing Hormone Receptor and Their Indispensable Role in the Ovulatory Process of the Medaka
por: Ogiwara, Katsueki, et al.
Publicado: (2013)

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.
por: Jungwirth, A., et al.
Publicado: (1997)

Response of the corpus luteum to luteinizing hormone.
por: Niswender, G D
Publicado: (1981)

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125
por: Seitz, Stephan, et al.
Publicado: (2014)

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
por: Philip, P. A., et al.
Publicado: (1993)

Luteinizing Hormone-Releasing Hormone Distribution in the Anterior Hypothalamus of the Female Rats
por: Castañeyra-Ruiz, Leandro, et al.
Publicado: (2013)

The utilization of basal luteinizing hormone in combination with the basal luteinizing hormone and follicle-stimulating hormone ratio as a diagnostic tool for central precocious puberty in girls
por: Chotipakornkul, Nuntika, et al.
Publicado: (2023)

Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome
por: Chun, Sungwook
Publicado: (2014)

Luteinizing hormone and its dilemma in ovulation induction
por: Kumar, Pratap, et al.
Publicado: (2011)

Ganirelix and the prevention of premature luteinizing hormone surges
por: Mannaerts, Bernadette
Publicado: (2023)

Do basal Luteinizing Hormone and Luteinizing Hormone/Follicle-Stimulating Hormone Ratio Have Significance in Prognosticating the Outcome of In vitro Fertilization Cycles in Polycystic Ovary Syndrome?
por: Singh, Neeta, et al.
Publicado: (2021)

Do Basal Luteinizing Hormone and Luteinizing Hormone/ Follicle-Stimulating Hormone Ratio have Significance in Prognosticating the Outcome of In vitro Fertilization Cycles in Polycystic Ovary Syndrome?
por: Neeta, Singh, et al.
Publicado: (2021)

Do Basal Luteinizing Hormone and Luteinizing Hormone/Follicle- Stimulating Hormone Ratio have Significance in Prognosticating the Outcome of In vitro Fertilization Cycles in Polycystic Ovary Syndrome?
por: Sookaromdee, Pathum, et al.
Publicado: (2021)

Luteinizing hormone beta gene polymorphism and its effect on semen quality traits and luteinizing hormone concentrations in Murrah buffalo bulls
por: Reen, Jagish Kour, et al.
Publicado: (2018)

Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
por: Spicer, Darcy V, et al.
Publicado: (2000)

The Roles of Luteinizing Hormone, Follicle-Stimulating Hormone and Testosterone in Spermatogenesis and Folliculogenesis Revisited
por: Oduwole, Olayiwola O., et al.
Publicado: (2021)

The crystal structure of the β subunit of luteinizing hormone and a model for the intact hormone
por: Larson, Steven B., et al.
Publicado: (2019)

Topographical localization of the receptors for luteinizing hormone- releasing hormone on the surface of dissociated pituitary cells
Publicado: (1977)

Basal luteinizing hormone and follicular stimulating hormone: is it sufficient for the diagnosis of precocious puberty in girls?
por: Lee, Dong Seong, et al.
Publicado: (2013)

Effects of growth hormone administration on luteinizing hormone secretion in healthy older men and women
por: Muniyappa, Ranganath, et al.
Publicado: (2017)

Effect of follicle-stimulating hormone and luteinizing hormone levels on egg-laying frequency in hens
por: Prastiya, Ragil Angga, et al.
Publicado: (2022)

The enigma of the gonadotropin-releasing hormone pulse frequency governing individual secretion of luteinizing hormone and follicle-stimulating hormone
por: Lambalk, Cornelis B.
Publicado: (2023)

Genetic Models for the Study of Luteinizing Hormone Receptor Function
por: Narayan, Prema
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_62qm91jklaf99spd8eorf9nuse